

Discussions with leaders: *JNM* editor-in-chief Johannes Czernin, with Thomas Hope, continues a series of interviews with leaders in nuclear and molecular imaging and therapy in a conversation with Lou Marzella, MD, PhD, about FDA perspectives on radiopharmaceuticals. **Page 881**

Pharmacogenomics in radionuclide therapy: Scott and Bodei provide an overview of the importance of considering individual germline and somatic mutations, as well as gene expression profiling, in predicting efficacy and toxicity across the spectrum of radionuclide treatment strategies. **Page 884**

Nuclear medicine in benign thyroid disease: Mariani and colleagues offer an educational review of clinical manifestations, pathophysiology, imaging modalities, and therapy of non-toxic nodular goiter, hypothyroidism, and thyroiditis. **Page 886**

Immunometabolism and atherosclerosis: Mannes and Tavakoli focus on recent advances in understanding of immunometabolism of atherosclerosis, with an emphasis on macrophages, and preview promising metabolic imaging approaches using ^{18}F -FDG and other PET radiotracers. **Page 896**

Nuclear medicine in The Netherlands: Czernin and Herrmann look at the implications of the 2015 creation of combined Dutch nuclear medicine and radiology residencies, specialty boards, and program review committees. **Page 903**

Dutch integrated residency training: Velleman and colleagues report on the results of a questionnaire exploring the reasons that residents chose to enter the nuclear medicine subspecialty in the integrated nuclear medicine and radiology residency program in The Netherlands. **Page 905**

Cognitive recovery in chronic COVID-19: Blazhenets and colleagues correlate clinical cognitive assessments and ^{18}F -FDG PET images from COVID-19 patients at subacute and chronic stages to examine the time-course of post-COVID impairment. **Page 910**

Beyond VISION: Fendler and colleagues detail the likely future effects of positive results announced earlier this year for the randomized phase III Vascular Events in Noncardiac Surgery Cohort Evaluation study on ^{177}Lu -PSMA-617 radioligand therapy. **Page 916**

^{18}F -FET PET for temozolomide monitoring: Ceccon and colleagues compare the value of contrast-enhanced MR imaging and ^{18}F -FET PET for response assessment in glioma patients after adjuvant temozolomide chemotherapy. **Page 918**

Anti-PD-1 response in NSCLC: Ayati and colleagues explore correlations between survival outcome and response assessment by PERCIST (version 1.0), immunotherapy-modified PERCIST, RECIST (version 1.1), and immunotherapy-modified RECIST in patients with non-small cell lung cancer. **Page 926**

^{11}C -Sorafenib and ^{15}O -H $_2$ O PET: Mammatas and colleagues investigate whether ^{11}C -sorafenib and ^{15}O -H $_2$ O PET have potential to predict sorafenib treatment efficacy in patients with advanced solid malignancies. **Page 934**

PARP1 cervical tumor identification: Demétrio De Souza França and colleagues describe the use of a fluorescent PARP1 inhibitor as an optical imaging agent to specifically target PARP1 expression, with potential to improve identification of tumor cells during colposcopy. **Page 941**

Iron-targeted theranostics for cancer: Zhao and colleagues test whether tumor uptake of the novel cytosolic labile iron pool-sensing radiotracer ^{18}F -trioxolane aligns with tumor sensitivity to LIP-targeted therapies. **Page 949**

Imaging calreticulin to detect cell death: Kim and colleagues assess the use of a calreticulin-specific binding peptide for imaging ecto-CRT during immunogenic cell death and its utility for early prediction of treatment response. **Page 956**

PSMA PET/CT in BCP: Meijer and colleagues report on a study designed to determine the role of ^{18}F -DCFPyL or ^{68}Ga -PSMA-11 PET/CT imaging in patients with prostate cancer who experience biochemical persistence after robot-assisted laparoscopic radical prostatectomy. **Page 961**

Correct detection rate of ^{18}F -rhPSMA-7 for BCR: Chantadisai and colleagues use composite validation to describe the detection rate, positive predictive value, and correct detection rate of ^{18}F -rhPSMA-7 PET/CT in biochemical recurrence of prostate cancer after radical prostatectomy. **Page 968**

RLT in prostate cancer: Prasad and colleagues present results on 2 case experiences with the synergistic effects of immunotherapy with pembrolizumab or sequentially after olaparib to overcome the limitations of radioligand therapy with ^{177}Lu -PSMA in metastasized castration-resistant prostate cancer. **Page 975**

^{213}Bi - and ^{225}Ac -based radiotherapeutics: Banerjee and colleagues synthesize ^{213}Bi - and ^{225}Ac -labeled α -particle-emitting analogs of a low-molecular-weight compound for preclinical evaluation in PSMA-targeted treatment of prostate cancer. **Page 980**

PSMA RLT proteomics/phosphoproteomics: Stuparu and colleagues investigate the proteome and phosphoproteome in a mouse model of prostate cancer to identify signaling adaptations triggered by PSMA radioligand therapy. **Page 989**

β -Receptor in chronotropic incompetence: Goto and colleagues explore cardiac β -adrenergic receptor density in patients with chronotropic incompetence without heart failure using ^{11}C -CGP12177 cardiac PET. **Page 996**

Universal readout of ^{18}F amyloid tracers: Bischof and colleagues document the comparability of 3 approved visual rating protocols to classify a scan as amyloid-positive or -negative, as applied by groups of experts and non-experts to all 3 amyloid tracers. **Page 999**

Single-time-point dosimetry: Hou and colleagues analyze 2 single-time-point dosimetry methods, evaluate dose errors for several radiopharmaceuticals based on effective half-life distribution, and make recommendations for improved personalized dosimetry using simplified imaging schemes. **Page 1006**

$^{132}\text{La}/^{225}\text{Ac}$ theranostics: Aluicio-Sarduy and colleagues describe preclinical work exploring the utility of ^{132}La as a PET imaging surrogate for ^{225}Ac using a DOTA-based, tumor-targeting alkylphosphocholine. **Page 1012**

Liver enzyme elevation after ^{177}Lu -PSMA: Treiber and colleagues detail the case study of a patient presenting with adverse events after ^{177}Lu -PSMA radioligand therapy for castration-resistant prostate cancer. **Page 1016**